Metraipolis › archive › dc_4758ffdf3a39

Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1 — Europe PMC PMID:38551976

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38551976
DOI
10.1371/journal.pcbi.1011518
License (as archived)
CC0-1.0
Archived
2026-10-06T20:05:56.851Z
SHA-256 of the archived text
57b8314f11b8d6b64b3c4171b0298da8964354daa86e0fd8e0f3abf8a3bb0f2c
Stable URL of this page
https://metraipolis.com/documento/dc_4758ffdf3a39

How to cite

Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1 — Europe PMC PMID:38551976 — Europe PMC (en), https://europepmc.org/article/MED/38551976 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_4758ffdf3a39 (Metraipolis archive dc_4758ffdf3a39, sha256 57b8314f11b8d6b64b3c4171b0298da8964354daa86e0fd8e0f3abf8a3bb0f2c)
BibTeX
@misc{dc4758ffdf3a39,
  title = {Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1 — Europe PMC PMID:38551976},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38551976},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_4758ffdf3a39; sha256 57b8314f11b8d6b64b3c4171b0298da8964354daa86e0fd8e0f3abf8a3bb0f2c},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38551976. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

PGT121 is a broadly neutralizing antibody in clinical development for the treatment and prevention of HIV-1 infection via passive administration. PGT121 targets the HIV-1 V3-glycan and demonstrated potent antiviral activity in a phase I clinical trial. Resistance to PGT121 monotherapy rapidly occurred in the majority of participants in this trial with the sampled rebound viruses being entirely resistant to PGT121 mediated neutralization. However, two individuals experienced long-term ART-free viral suppression following antibody infusion and retained sensitivity to PGT121 upon viral rebound. Here, we develop mathematical models of the HIV-1 dynamics during this phase I clinical trial. We utilize these models to understand the dynamics leading to PGT121 resistance and to identify the mechanisms driving the observed long-term viral control. Our modeling highlights the importance of the relative fitness difference between PGT121 sensitive and resistant subpopulations prior to treatment. Specifically, by fitting our models to data, we identify the treatment-induced competitive advantage of previously existing or newly generated resistant population as a primary driver of resistance. Finally, our modeling emphasizes the high neutralization ability of PGT121 in both participants who exhibited long-term viral control.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2024 (prima pubblicazione 2024-03-29).
Identificativi: PMID 38551976 · PMCID PMC11006161 · DOI 10.1371/journal.pcbi.1011518.
Descrittori MeSH principali: HIV-1; HIV Infections.
Pagina: https://europepmc.org/article/MED/38551976 — https://doi.org/10.1371/journal.pcbi.1011518. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T18:30:56.383Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.